Stem Cell Therapy Market: Information by Cell Source, by Type, by Application, by End User, and by Region —Forecast till 2027
出 版 商：Market Research Future
出版日期：2021/08/01
頁 數：132頁
文件格式：PDF
價 格：
USD 4,450 (Single-User License)
USD 6,250 (Global-User License)
USD 6,250 (Global-User License)
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENT
CHAPTER 1. REPORT PROLOGUE
CHAPTER 2. MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.2.1 RESEARCH OBJECTIVE
2.2.2 ASSUMPTIONS
2.2.3 LIMITATIONS
CHAPTER 3. RESEARCH METHODOLOGY
3.1 INTRODUCTION
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
CHAPTER 4. MARKET DYNAMICS
4.1 DRIVERS
4.2 RESTRAINTS
4.3 OPPORTUNITIES
4.4 CHALLENGES
4.5 MACROECONOMIC INDICATORS
4.6 TECHNOLOGY TRENDS & ASSESSMENT
CHAPTER 5. MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF RIVALRY
5.2 VALUE CHAIN ANALYSIS
5.3 INVESTMENT FEASIBILITY ANALYSIS
5.4 PRICING ANALYSIS
CHAPTER 6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE
6.1 INTRODUCTION
6.2 ALLOGENEIC
6.3 AUTOLOGOUS
CHAPTER 7. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION
7.1 INTRODUCTION
7.2 MEDICINE
7.3 CARDIOVASCULAR DISEASES
7.4 BONE REGENERATION
7.5 NEURODEGENERATIVE DISORDERS
7.6 WOUND HEALING
7.7 TREATMENT OF EYES
7.8 HEMATOPOIETIC DISORDERS
7.9 METABOLIC DISORDERS
7.10 CANCER
7.11 IMMUNODEFICIENCY
7.12 DIABETES
CHAPTER 8. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE
8.1 INTRODUCTION
8.2 ADIPOSE TISSUE
8.3 BONE MARROW
8.3 NEURAL
8.4 EMBRYO/CORD BLOOD-DERIVED
8.5 IPSCS
CHAPTER 9. GLOBAL STEM CELL THERAPY MARKET, BY END -USER
9.1 INTRODUCTION
9.2 BIOTECHNOLOGY COMPANIES
9.3 HOSPITALS & RESEARCH INSTITUTES
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.5 STEM CELL BANKS
CHAPTER 10. GLOBAL STEM CELL THERAPY MARKET, BY REGION
10.1 INTRODUCTION
10.2 AMERICA
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 SOUTH AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 ITALY
10.3.1.4 SPAIN
10.3.1.5 UK
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 REPUBLIC OF KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 UNITED ARAB EMIRATES
10.5.2 SAUDI ARABIA
10.5.3 OMAN
10.5.4 KUWAIT
10.5.5 QATAR
10.5.6 REST OF THE MIDDLE EAST & AFRICA
CHAPTER 11. COMPANY LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS
11.3 KEY DEVELOPMENT & STRATEGIES
11.3.1 KEY DEVELOPMENTS
CHAPTER 12 COMPANY PROFILES
12.1 OSIRIS THERAPEUTICS, INC.
12.1.1 COMPANY OVERVIEW
12.1.2 PRODUCT TYPE OVERVIEW
12.1.3 FINANCIALS
12.2.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.2 MEDIPOST CO., LTD.
12.2.1 COMPANY OVERVIEW
12.2.2 PRODUCT TYPE OVERVIEW
12.2.3 FINANCIAL OVERVIEW
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.3 ANTEROGEN CO., LTD.
12.3.1 COMPANY OVERVIEW
12.3.2 PRODUCT TYPE OVERVIEW
12.3.3 FINANCIAL OVERVIEW
12.3.4 KEY DEVELOPMENT
12.3.5 SWOT ANALYSIS
12.4 PHARMICELL CO., LTD.
12.4.1 COMPANY OVERVIEW
12.4.2 PRODUCT TYPE/BUSINESS SEGMENT OVERVIEW
12.4.3 FINANCIAL OVERVIEW
12.4.4 KEY DEVELOPMENT
12.4.5 SWOT ANALYSIS
12.5 HOLOSTEM TERAPIE AVANZATE S.R.L.
12.5.1 COMPANY OVERVIEW
12.5.2 PRODUCT TYPE OVERVIEW
12.5.3 FINANCIAL OVERVIEW
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.6 JCR PHARMACEUTICALS CO., LTD.
12.6.1 COMPANY OVERVIEW
12.6.2 PRODUCT TYPE OVERVIEW
12.6.3 FINANCIAL OVERVIEW
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.7 NUVASIVE, INC
12.7.1 OVERVIEW
12.7.2 PRODUCT TYPE OVERVIEW
12.7.3 FINANCIALS
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.8 RTI SURGICAL, INC.
12.8.1 OVERVIEW
12.8.2 PRODUCT TYPE OVERVIEW
12.8.3 FINANCIALS
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.9 ALLOSOURCE
12.9.1 OVERVIEW
12.9.2 PRODUCT TYPE OVERVIEW
12.9.3 FINANCIALS
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.10 THERMO FISHER SCIENTIFIC
12.10.1 OVERVIEW
12.10.2 PRODUCT TYPE OVERVIEW
12.10.3 FINANCIALS
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.11 OTHERS
CHAPTER 14 APPENDIX
CHAPTER 1. REPORT PROLOGUE
CHAPTER 2. MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.2.1 RESEARCH OBJECTIVE
2.2.2 ASSUMPTIONS
2.2.3 LIMITATIONS
CHAPTER 3. RESEARCH METHODOLOGY
3.1 INTRODUCTION
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
CHAPTER 4. MARKET DYNAMICS
4.1 DRIVERS
4.2 RESTRAINTS
4.3 OPPORTUNITIES
4.4 CHALLENGES
4.5 MACROECONOMIC INDICATORS
4.6 TECHNOLOGY TRENDS & ASSESSMENT
CHAPTER 5. MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF RIVALRY
5.2 VALUE CHAIN ANALYSIS
5.3 INVESTMENT FEASIBILITY ANALYSIS
5.4 PRICING ANALYSIS
CHAPTER 6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE
6.1 INTRODUCTION
6.2 ALLOGENEIC
6.3 AUTOLOGOUS
CHAPTER 7. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION
7.1 INTRODUCTION
7.2 MEDICINE
7.3 CARDIOVASCULAR DISEASES
7.4 BONE REGENERATION
7.5 NEURODEGENERATIVE DISORDERS
7.6 WOUND HEALING
7.7 TREATMENT OF EYES
7.8 HEMATOPOIETIC DISORDERS
7.9 METABOLIC DISORDERS
7.10 CANCER
7.11 IMMUNODEFICIENCY
7.12 DIABETES
CHAPTER 8. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE
8.1 INTRODUCTION
8.2 ADIPOSE TISSUE
8.3 BONE MARROW
8.3 NEURAL
8.4 EMBRYO/CORD BLOOD-DERIVED
8.5 IPSCS
CHAPTER 9. GLOBAL STEM CELL THERAPY MARKET, BY END -USER
9.1 INTRODUCTION
9.2 BIOTECHNOLOGY COMPANIES
9.3 HOSPITALS & RESEARCH INSTITUTES
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.5 STEM CELL BANKS
CHAPTER 10. GLOBAL STEM CELL THERAPY MARKET, BY REGION
10.1 INTRODUCTION
10.2 AMERICA
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 SOUTH AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 ITALY
10.3.1.4 SPAIN
10.3.1.5 UK
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 REPUBLIC OF KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 UNITED ARAB EMIRATES
10.5.2 SAUDI ARABIA
10.5.3 OMAN
10.5.4 KUWAIT
10.5.5 QATAR
10.5.6 REST OF THE MIDDLE EAST & AFRICA
CHAPTER 11. COMPANY LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS
11.3 KEY DEVELOPMENT & STRATEGIES
11.3.1 KEY DEVELOPMENTS
CHAPTER 12 COMPANY PROFILES
12.1 OSIRIS THERAPEUTICS, INC.
12.1.1 COMPANY OVERVIEW
12.1.2 PRODUCT TYPE OVERVIEW
12.1.3 FINANCIALS
12.2.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.2 MEDIPOST CO., LTD.
12.2.1 COMPANY OVERVIEW
12.2.2 PRODUCT TYPE OVERVIEW
12.2.3 FINANCIAL OVERVIEW
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.3 ANTEROGEN CO., LTD.
12.3.1 COMPANY OVERVIEW
12.3.2 PRODUCT TYPE OVERVIEW
12.3.3 FINANCIAL OVERVIEW
12.3.4 KEY DEVELOPMENT
12.3.5 SWOT ANALYSIS
12.4 PHARMICELL CO., LTD.
12.4.1 COMPANY OVERVIEW
12.4.2 PRODUCT TYPE/BUSINESS SEGMENT OVERVIEW
12.4.3 FINANCIAL OVERVIEW
12.4.4 KEY DEVELOPMENT
12.4.5 SWOT ANALYSIS
12.5 HOLOSTEM TERAPIE AVANZATE S.R.L.
12.5.1 COMPANY OVERVIEW
12.5.2 PRODUCT TYPE OVERVIEW
12.5.3 FINANCIAL OVERVIEW
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.6 JCR PHARMACEUTICALS CO., LTD.
12.6.1 COMPANY OVERVIEW
12.6.2 PRODUCT TYPE OVERVIEW
12.6.3 FINANCIAL OVERVIEW
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.7 NUVASIVE, INC
12.7.1 OVERVIEW
12.7.2 PRODUCT TYPE OVERVIEW
12.7.3 FINANCIALS
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.8 RTI SURGICAL, INC.
12.8.1 OVERVIEW
12.8.2 PRODUCT TYPE OVERVIEW
12.8.3 FINANCIALS
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.9 ALLOSOURCE
12.9.1 OVERVIEW
12.9.2 PRODUCT TYPE OVERVIEW
12.9.3 FINANCIALS
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.10 THERMO FISHER SCIENTIFIC
12.10.1 OVERVIEW
12.10.2 PRODUCT TYPE OVERVIEW
12.10.3 FINANCIALS
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.11 OTHERS
CHAPTER 14 APPENDIX
